| Christopher Leiske has over 15 years of industrial experience in Protein and ADC characterization, having spent the last 12 years at Seagen. He is currently a Senior Scientist in the Analytical Sciences department where he manages a team contributing to Seagen’s complex early pre-clinical and clinical pipeline. In addition, he leads up Seagen’s Early Molecule Assessment team, which specializes in early engagement and pre-development collaborations between Seagen’s CMC and Research organization. Prior to Analytical Sciences, Chris spent time in the Research Conjugation and Protein Engineering groups at Seagen, having a strong interest in discovery and development of novel mAb and ADC modalities. |